Press Releases AstraZeneca PLC Nasdaq Stockholm

Equities

AZN

GB0009895292

Real-time Estimate Cboe Europe Other stock markets 07:04:38 27/06/2024 pm IST			5-day change	1st Jan Change
1,670 ^SEK	-0.21%		+1.79%	+23.64%

12:39pm	US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	RE
26/06	European Equities Close Lower in Wednesday Trading	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Astrazeneca - Tagrisso with the addition of chemotherapy approved in China as 1st-line treatment for patients with EGFR-mutated advanced lung cancer	06:02pm	AQ
Astrazeneca - IMFINZI demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial	26/06	AQ
Astrazeneca - Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer	26/06	AQ
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial	25/06	BU
AstraZeneca : Update on Imfinzi ADJUVANT BR.31 trial	25/06	PU
AstraZeneca : Imfinzi improved EFS and OS in bladder cancer	25/06	PU
Astrazeneca - Update on the CAPItello-290 Phase III trial for Truqap plus chemotherapy in advanced or metastatic triple-negative breast cancer	19/06	AQ
Squamous Cell Carcinoma Pipeline 2024 \| FDA Approvals, Clinical Trials, Therapies, MOA, ROA \| Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna	19/06	AQ
AstraZeneca - IMFINZI plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer	18/06	AQ
AstraZeneca : Update on CAPItello-290 Phase III trial	18/06	PU
Astrazeneca - Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial	17/06	AQ
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer	17/06	BU
AstraZeneca : Imfinzi plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer Form 6 K	17/06	PU
AstraZeneca : Imfinzi approved in the US for endometrial cancer	17/06	PU
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial	16/06	BU
AstraZeneca : Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial	16/06	PU
AstraZeneca - Farxiga approved in the US for the treatment of paediatric type-2 diabetes	13/06	AQ
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes	13/06	BU
AstraZeneca : Transaction by Person Discharging Managerial Responsibilities Form 6 K	12/06	PU
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development (CRDL,JAZZ, NVO, AZN, SNY)	11/06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 09:32 pm IST